NASDAQ:MIST
Milestone Pharmaceuticals Inc. Stock News
$1.50
-0.0300 (-1.96%)
At Close: May 31, 2024
Here's Why We're Not Too Worried About Milestone Pharmaceuticals's (NASDAQ:MIST) Cash Burn Situation
02:22pm, Tuesday, 04'th Feb 2020
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Daily Insider Ratings Round Up 1/13/20
01:57am, Wednesday, 15'th Jan 2020
Tables of the top insider purchases and sales filed with the SEC on 1/13/20, based on dollar value. Dollar values often do not equate with significance when it
Should You Avoid Milestone Pharmaceuticals Inc. (MIST)?
11:20pm, Friday, 20'th Dec 2019
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks a
Canadian VC at $5.1B at 3Qs 2019, with historical record $6.5B within reach
12:00pm, Wednesday, 27'th Nov 2019
Canadian VC at $5.1B at 3Qs 2019, with historical record $6.5B within reach
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
12:00pm, Thursday, 14'th Nov 2019
MONTREAL and CHARLOTTE, N.C. , Nov. 14, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that Joseph G. Oliveto , President and Chief Executive Officer, will present
Milestone Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Corporate Update
12:00pm, Wednesday, 13'th Nov 2019
Milestone Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Corporate Update
Milestone Pharmaceuticals Announces First Patient Enrolled in NODE-303 Open-label Safety Study of Etripamil in PSVT
11:00am, Thursday, 03'rd Oct 2019
MONTREAL and CHARLOTTE, N.C. , Oct. 3, 2019 /CNW/ -- Milestone Pharmaceuticals Inc. (MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripami
Milestone Pharmaceuticals Announces Appointment of Amit Hasija as Chief Financial Officer and Executive Vice President of Corporate Development
Milestone Pharmaceuticals Provides Positive Regulatory Updates for Etripamil Pivotal Program in PSVT and Reports Second Quarter 2019 Financial Results
